Cadila Healthcare Ltd - 532321 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended on December 31, 2019. Cadila Healthcare Ltd - 532321 - Loss of Share Certificate / Issue of Duplicate Share Certificate
Loss of Share Certificate / Issue of Duplicate Share Certificate. Cadila Healthcare Ltd - 532321 - Shareholding for the Period Ended December 31, 2019
Cadila Healthcare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2019. For more details, kindly Click here CADILA HEALTHCARE LTD. - 532321 - Notification
This is to bring to the notice of the members of the exchange and the investors at large, that today's media report about Cadila Healthcare Ltd's plans to sell two of its divisions is a speculative one. We wish to state that the Company has no such plans. CADILA HEALTHCARE LTD. - 532321 - Notification
The USFDA inspected the Company's topical manufacturing facility located in Ahmedabad from 16th to 20th December, 2019. At the end of the inspection, no observation (483) is issued. Cadila Healthcare Ltd - 532321 - Notification
The USFDA inspected the Company's topical manufacturing facility located in Ahmedabad from 16th to 20th December, 2019. At the end of the inspection, no observation (483) is issued. Cadila Healthcare Ltd - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate / issue of duplicate share certificate under regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations) CADILA HEALTHCARE LTD. - 532321 - Loss of Share Certificate / Issue of Duplicate Share Certificate
Loss of Share Certificate / Issue of Duplicate Share Certificate.
Cadila Healthcare gains 4% on launch of anti-diabetic tablet in India
Vinglyn and Vinglyn M will be marketed by Zydus Healthcare.